Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial Environment (ENVIEANCILLAIR)

7 juli 2026 uppdaterad av: Centre Hospitalier Intercommunal Creteil

Among children aged ≤ 6 months included in the ENVIE study, the ENVIE_ancillaire study will be offered to cases of RSV infection or to controls. The study involves a nasopharyngeal swab using a FLOQ-SWAB™ swab and a fingertip sample (dextro type). These samples will be collected specifically for the purpose of studying immunity.

A blood sample may also be requested for children weighing ≥5 kg who are included in the ENVIE_ancillaire study. The purpose of this sample collection will be to conduct an advanced immunological study

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Among children aged ≤ 6 months included in the ENVIE study, the ENVIE_ancillaire study will be offered to cases of RSV infection or to controls. The study involves a nasopharyngeal swab using a FLOQ-SWAB™ swab and a fingertip sample (dextro type). This sample collection will be carried out specifically for the study of immunity. Innate immune mediators (type I, II and III IFNs) and key inflammatory molecules (IL-6, TNF-alpha, IL-10) will be quantified, and adaptive immunity will be analysed by measuring local immunoglobulin titres (IgG, A, M, subclasses and specific antibodies against the inactivated virus) from the nasopharyngeal swab and blood samples absorbed onto filter paper. A blood sample may also be offered to children weighing ≥5 kg who are included in the ENVIE_ancillaire study. The purpose of this sample collection will be to conduct an advanced immunological study (identification of the host's protein, cellular and transcriptomic response). Finally, the bacterial microbiome (16S RNA) and the soluble virome will be characterised by high-throughput sequencing.

Studietyp

Observationell

Inskrivning (Beräknad)

110

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

  • Frankrike
      • Créteil, Frankrike
        • Rekrytering
        • Chi Creteil
        • Kontakt:
          • Mickaël SHUM
      • Paris, Frankrike
        • Rekrytering
        • CHU Robert-Debré
        • Kontakt:
          • Naïm OULDALI, phD
      • Paris, Frankrike
        • Rekrytering
        • CHU Necker
        • Kontakt:
          • Julie TOUBIANA, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

N/A

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Among children aged 6 months or younger included in the ENVIE study, the ENVIE_ancillaire study will be offered to those with RSV infection or to the control group.

Beskrivning

Inclusion Criteria:

  • Written consent to take part in the study
  • Registered with a social security scheme

Cases:

  • Children aged 6 months or under included in the ENVIE study. Treated for bronchiolitis caused by RSV
  • Admitted to hospital following a visit to the paediatric A&E department

Control group:

Children aged 6 months or under included in the ENVIE study. Admitted to a standard ward or a Short-Stay Unit, or having attended the paediatric A&E department

For one of the following reasons:

  • Febrile urinary tract infection, without acute ENT or respiratory symptoms
  • Acute gastroenteritis, without acute ENT or respiratory symptoms
  • Infant colic without fever, without ENT or acute respiratory condition
  • Weight stagnation or feeding difficulties without fever, without acute ENT or respiratory symptoms
  • Neonatal jaundice without fever, without acute ENT or respiratory symptoms
  • Unexplained crying without fever, without acute ENT or respiratory symptoms
  • Head injury, without acute ENT or respiratory symptoms
  • Admitted for acute surgical conditions, without fever, without acute ENT or respiratory symptoms
  • Nappy rash, without fever, without acute ENT or respiratory symptoms
  • Fracture, without fever, without acute ENT or respiratory symptoms.

Exclusion Criteria:

  • Refusal to participate by the legal representative
  • Administration of palivizumab
  • Maternal vaccination against RSV.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Case
Children aged 6 months or under included in the ENVIE study, treated for bronchiolitis caused by RSV
Biologisk: a study of the mucosal immune signature associated with hospitalised RSV bronchiolitis

Once those with parental authority have confirmed their willingness for their child to take part in the research and written consent has been obtained, the following samples may be collected:

  • A nasopharyngeal swab
  • A 'dextro' blood sample with a blot on filter paper. The nasopharyngeal samples and blotting papers will be stored at -20°C (or -80°C if possible) and transported to the Pasteur Institute as soon as possible (just-in-time).

il sera possible de proposer un prélèvement supplémentaire dans le cadre d'une étude immunologique avancée, chez les nourrissons ≥ 5 kg. Ce prélèvement comprend :

  • Un tube hépariné pour plasmatèque et cellulotèque : 5 mL
  • Un tube PAX gene pediatrique pour RNAtèque : 0,5 mL
Control group

Children aged 6 months or under included in the ENVIE study, admitted to a standard ward or a Short-Stay Unit, or who have attended the paediatric A&E department

For one of the following reasons:

  • Febrile urinary tract infection, without acute ENT or respiratory symptoms
  • Acute gastroenteritis, without acute ENT or respiratory symptoms
  • Infant colic without fever, without ENT or
  • Weight stagnation or feeding difficulties without fever, without acute ENT or respiratory symptoms
  • Neonatal jaundice without fever, without acute ENT or respiratory symptoms
  • Unexplained crying without fever, without acute ENT or respiratory symptoms
  • Head injury, without acute ENT or respiratory symptoms
  • Treated for an acute surgical condition, without fever, without acute ENT or respiratory symptoms
  • Nappy rash, without fever, without acute ENT or respiratory symptoms,
  • Fracture, without fever, without acute ENT or respiratory symptoms.
Biologisk: a study of the mucosal immune signature associated with hospitalised RSV bronchiolitis

Once those with parental authority have confirmed their willingness for their child to take part in the research and written consent has been obtained, the following samples may be collected:

  • A nasopharyngeal swab
  • A 'dextro' blood sample with a blot on filter paper. The nasopharyngeal samples and blotting papers will be stored at -20°C (or -80°C if possible) and transported to the Pasteur Institute as soon as possible (just-in-time).

il sera possible de proposer un prélèvement supplémentaire dans le cadre d'une étude immunologique avancée, chez les nourrissons ≥ 5 kg. Ce prélèvement comprend :

  • Un tube hépariné pour plasmatèque et cellulotèque : 5 mL
  • Un tube PAX gene pediatrique pour RNAtèque : 0,5 mL

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Mucosal cytokine profile of patients (type I and III interferons, pro-inflammatory cytokines)
Tidsram: Baseline
Baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Centre Hospitalier Intercommunal Creteil

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 december 2024

Primärt slutförande (Beräknad)

5 december 2026

Avslutad studie (Beräknad)

5 december 2026

Studieregistreringsdatum

Först inskickad

7 juli 2026

Först inskickad som uppfyllde QC-kriterierna

7 juli 2026

Första postat (Faktisk)

13 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

7 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2024-A01208-39

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera